Peptide Initiative

Peptide profile · Immune

Vilon

Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance

Limited human trialsResearch compound
Short plasma half-life typical of dipeptidesHalf-life (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids
Absorbed via intestinal peptide transportersBioavailability (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure
275.3Molecular weight, g/mol

Molecular formula

C11H21N3O5

CAS number
45234-02-4
PubChem
7010502
Developed · 1970s-1980s (characterized as part of Khavinson's systematic peptide bioregulator research program beginning in 1973)
Vladimir Khavinson, Saint Petersburg Institute of Bioregulation and Gerontology, Russia

Amino acid sequence

H-Lys-Glu-OH (KE dipeptide — L-Lysine-L-Glutamic acid)

Immune System RevivalVilon wakes up your thymus gland, the organ that trains immune cells, helping your body make more infection-fighting T cells as you age .

9.4

Healthy AgingThis peptide turns on SIRT1, a longevity gene that helps cells stay young and healthy, while calming down inflammation throughout your body .

9.1

Digestive SupportVilon boosts digestive enzymes in your gut, helping your body break down and absorb nutrients better, especially as you get older.

8.2

Ratings out of 10.

200 – 500mcg

Every documented dose level

PhaseDoseFrequencyRoute
Days 5-10200–500 mcgOnce dailySubcutaneous injection
Days 10-12500 mcgOnce dailySubcutaneous injection
Days 10-12500 mcgOnce dailyIntramuscular injection
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for immune system restoration in aging individuals with declining thymic function & adjunctive immunomodulatory support during cancer treatment protocols

Best for

  • Immune system restoration in aging individuals with declining thymic function

    Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Adjunctive immunomodulatory support during cancer treatment protocols

    Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity

    Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Comprehensive Khavinson bioregulator protocols for anti-aging and immune support

    Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for immune supportConsult your healthcare provider for alternatives to Vilon based on your specific needs and medical history
Alternative immune-modulating peptidesThymosin Alpha-1LL-37Thymulin
Non-peptide immune supportVitamin D3Zinc supplementationBeta-glucans

Do not use if

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune disease in flare without medical supervision
  • Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Vilon use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Vilon with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Vilon injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature.

Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk.

Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.

Safety data comes primarily from Russian clinical experience and unpublished manufacturer studies; limited peer-reviewed Western data exists. No Phase 3 controlled efficacy trials have been published in major journals.

Immunostimulatory mechanism could theoretically exacerbate autoimmune conditions, requiring baseline immune status assessment. Long-term safety beyond 2-3 months of use is incompletely characterized in English-language literature.


Common side effects · experienced by some users

Injection site reaction

Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. Common with injectable peptide bioregulators.

Management
Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.

Mild fatigue

Slight fatigue during the initial days as the immune system recalibrates in response to enhanced T-cell activation and cytokine modulation.

Management
Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.

Mild headache

Transient headache during the first few days of treatment, potentially related to immune activation and cytokine level changes.

Management
Ensure adequate hydration. Standard analgesics if needed. Usually self-limiting.

Digestive changes

Mild gastrointestinal changes (increased digestive activity, slight changes in bowel habits) reflecting Vilon's enhancement of digestive enzyme activity throughout the GI tract.

Management
Generally benign — indicates active enzyme normalization. Eat regular meals. Should stabilize within days.

Serious side effects

No documented serious adverse effects

No serious adverse events, drug dependence, organ toxicity, or allergic reactions have been reported across all published clinical studies. No lethal dose has been established in animal toxicology research — dose-escalation studies could not reach lethal endpoints.

Management
As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.

Less commonFlu-like symptoms

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Vilon
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Vilon should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeThymalin (natural thymic peptide complex — Vilon is the synthetic KE component; combining provides the full spectrum of thymic peptides alongside the purified active dipeptide) — May be used together under medical guidance.
  • SafeEpithalon (AEDG tetrapeptide — complementary pineal/melatonin bioregulator that supports neuroendocrine function alongside Vilon's immune support) — May be used together under medical guidance.
  • SafeVladonix (thymic peptide complex — provides additional thymic-derived peptides for comprehensive immune bioregulation) — May be used together under medical guidance.

With medications

  • CautionImmunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) — Vilon's immunostimulatory effects may counteract immunosuppression — Use with caution—discuss with your healthcare provider.
  • CautionHigh-dose corticosteroids — may interfere with Vilon's T-cell activation and cytokine regulation mechanisms — Use with caution—discuss with your healthcare provider.
  • CautionOther potent immunostimulants at high doses without medical supervision — risk of immune overactivation — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Vilon. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs days 1-5 (during treatment course)

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Gradual

(3-4 weeks)


How it works

Vilon is a skin and connective tissue support peptide that promotes collagen production, improves skin elasticity, and enhances wound healing through activation of fibroblast growth pathways.

The deeper mechanism

Vilon is a bioactive peptide derived from collagen and elastin-rich tissues that activates fibroblast growth factor (FGF) and transforming growth factor-beta (TGF-β) signaling in dermal fibroblasts.

These mechanisms upregulate type I and III collagen synthesis through COL1A1 and COL3A1 expression, increase hyaluronic acid production through enhanced hyaluronic acid synthase (HAS) activity, promote skin cell proliferation and differentiation, enhance basement membrane integrity, and improve wound healing through angiogenesis and tissue remodeling factor expression.


What to expect

  1. Days 1-5 (during treatment course)

    What you might notice

    • Minimal noticeable changes during the initial days — epigenetic mechanisms are building
    • Mild injection site reactions that resolve within hours
    • Possible mild fatigue or flu-like symptoms as immune modulation begins
    • The dipeptide-DNA interactions at SIRT1/PARP promoters are already underway

    What's normal

    • Effects are subtle initially — Vilon works at the gene expression level through DNA promoter binding
    • SIRT1 upregulation and PARP downregulation are beginning but protein synthesis changes take days
    • Thymocyte activation through the sphingomyelin pathway is starting to enhance T-cell development

    What's next

    • Continue daily injections for the full course duration (5-12 days)
    • Immune improvements and geroprotective effects will continue building
    • The most significant cellular changes occur during and shortly after the treatment course
  2. Week 1-4 (during and after treatment)

    What you might notice

    • Improved immune resilience — potentially fewer or shorter duration of common infections
    • Enhanced recovery from illness or physical stress
    • Improved energy levels and reduced fatigue as immune function normalizes
    • Better digestive function from enhanced enzyme activity

    What's normal

    • SIRT1 protein levels are significantly elevated (up to 8.2-fold), enhancing DNA repair and stress resistance
    • T-cell maturation (CD4+ and CD8+) is enhanced from thymocyte activation
    • Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are significantly reduced
    • These molecular changes translate into functional immune improvements over weeks

    What's next

    • Benefits continue to develop for weeks after the treatment course ends
    • Epigenetic modifications to SIRT1/PARP gene expression persist beyond active treatment
    • Plan the next course in 3-6 months to reinforce and extend benefits
  3. Month 1-6 (inter-course period)

    What you might notice

    • Sustained improvements in immune function and overall resilience
    • Ongoing geroprotective benefits from persistent SIRT1 upregulation
    • Reduced frequency and severity of age-related immune dysfunction
    • Benefits may gradually diminish over months, indicating readiness for the next course

    What's normal

    • Epigenetic modifications persist beyond the active treatment period
    • Khavinson protocols are designed as cyclical treatments with 3-6 month intervals
    • Each subsequent course reinforces and extends the benefits from previous treatments
    • Long-term clinical follow-up supports sustained benefits with repeated courses

    What's next

    • Begin the next Vilon course after 3-6 months
    • Consider combining with complementary bioregulators in rotation
    • Comprehensive anti-aging protocols may use Vilon alongside Epithalon, Cerluten, and others

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Vilon over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What is Vilon and how is it related to Thymalin?

Vilon is a synthetic dipeptide (Lys-Glu or KE) that was identified as one of the key immunomodulatory active components within Thymalin, a pharmaceutical containing natural thymic peptide extracts. While Thymalin contains a complex mixture of thymic peptides, Vilon is the purified synthetic version of just the KE dipeptide — offering the targeted immunomodulatory and geroprotective effects of this specific component. Studies have confirmed that the KE dipeptide drives much of Thymalin's T-cell activation, cytokine regulation, and anti-inflammatory activity.

How does Vilon compare to other Khavinson peptide bioregulators?

In direct comparisons, Vilon (KE) produces the most potent thymocyte proliferative effect among tested Khavinson bioregulators — superior to both Epithalon (AEDG, pineal bioregulator) and Cortagen (AEDP, brain bioregulator). Vilon also shows more pronounced activation of the sphingomyelin signal transduction pathway. While Epithalon specializes in pineal/melatonin function and Cortagen in neuroprotection, Vilon is the most potent immune-specific bioregulator in the Khavinson family.

What makes the SIRT1/PARP mechanism important for aging?

SIRT1 (sirtuin-1) is a NAD+-dependent deacetylase considered a master longevity regulator — it promotes DNA repair, telomere maintenance, oxidative stress resistance, and metabolic efficiency. PARP1/PARP2 compete with SIRT1 for NAD+ and are overexpressed during aging, depleting the NAD+ pool available for SIRT1 activity. Vilon rebalances this axis by upregulating SIRT1 (6-8.2 fold) while downregulating PARP1/PARP2 (2.1-5.3 fold), restoring the NAD+ allocation toward longevity pathways. This dual mechanism is considered one of the most direct interventions against fundamental aging mechanisms.

Can Vilon help cancer patients?

Published clinical evidence supports Vilon as an adjunctive therapy for cancer patients. In a study of elderly Stage III colorectal cancer patients, adding Vilon to standard radio/chemotherapy improved 2-year survival, reduced post-operative complications, prevented tumor recurrence and dissemination, and improved quality of life. In animal models, Vilon reduced urinary bladder tumor incidence from 75.5% to 56% with a 2-fold decrease in pre-neoplastic lesions. These oncostatic effects are attributed to activation of heterochromatin-silenced genes and inhibition of reactive oxygen species formation.

Why is Vilon only 2 amino acids long — can such a small peptide really be effective?

Vilon (Lys-Glu) is one of the smallest bioactive peptides known, and its efficacy has been extensively documented across dozens of peer-reviewed studies. The KE dipeptide achieves biological activity through direct interaction with specific DNA sequences (GCGG in B-form DNA, GGGC in nucleosomal DNA) in gene promoter regions. This ultra-short structure actually provides advantages: efficient cellular uptake via peptide transporters, direct nuclear penetration without carrier proteins, and rapid tissue distribution. The specificity comes not from the peptide's size but from its precise fit into DNA promoter sequences of target genes.

How does Vilon affect the immune system differently from conventional immunostimulants?

Unlike conventional immunostimulants that broadly activate immune responses, Vilon works through epigenetic gene regulation to restore proper immune function. It simultaneously enhances adaptive immunity (T-cell maturation via CD5/CD4/CD8 pathway activation) while reducing pathological inflammation (IL-1β, IL-6, TNF-α reduction). This dual immunomodulatory action — boosting beneficial immune responses while suppressing harmful inflammatory cascades — is fundamentally different from simple immunostimulation and explains why Vilon can be beneficial in both immune deficiency and inflammatory conditions.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Vilon, on one page.

Vilon dosing protocol

Medical disclaimer

Vilon is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

200 – 500 mcg Once daily · onset 3-4 weeks
Open the Vilon calculatorVilon calculator